1. Scrip
  2. >>Business
  3. >>Strategy

Boehringer's Expanded Venture Fund: Innovation First, Returns Second

 
• By Mandy Jackson

Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.

Euro currency

Boehringer Ingelheim GMBH has more than doubled the size of its corporate venture capital fund from €100m to €250m ($301.8m) to expand its US footprint and investment focus, while continuing to fund start-ups with technology of interest to the German pharmaceutical company.

Martin Heidecker, managing director of Boehringer Ingelheim Venture Fund (BIVF) in the US, told Scrip that BIVF's therapeutic interests have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip Phase II data from one trial for its Bharat Biotech-partnered shigella vaccine candidate is expected end-2025 and from the other beginning-2026, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

More from Business

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.